Solstice Advanced Materials (SOLS) is one of two companies teased in Gabe Marshank’s Market Maven “Ultimate ISO” presentation, the larger of the two by market value at roughly $10 billion, and the one that has traded up since the pitch was recorded. If you searched the ticker, here is what the promo actually claims, what the numbers show, and what to check before you treat a tease as a recommendation.

What the Promo Claims

The presentation does not name the stock outright, which is the standard tease structure, but the description points to Solstice Advanced Materials, a recently carved-out advanced-materials business. Marshank’s thesis is the ISO, or investable spinoff, framework: the company was separated from a parent, its shares were distributed mechanically, and the resulting orphan selling left a quality business priced below what its independent economics support. The promo pairs this with a sizing claim, calling the spinoff opportunity “more than 8X bigger” than the IPO wave it follows, and it leans on Marshank’s stated background, including a claim that he “banked more than $100,000,000” running money at hedge funds.

The Numbers

As of the October 27, 2026 close, Solstice Advanced Materials traded around $62.97, which sits above the roughly $60.23 level the tease implied, a gain of about 4.55%. At that price the company carries a market value near $10 billion, making it the larger of the two teased names by a wide margin. A business of that size is past the point where a spinoff discount alone moves the needle, which is the first thing to weigh against the “orphaned and cheap” framing: a $10 billion company is rarely invisible to the market, even on its first day as a standalone.

The Track Record

The credibility of the ISO pitch rests partly on how Marshank’s prior teased names have done. The presentation’s flagship example, Grail, the cancer-screening company, worked out well for subscribers who followed it. The less comfortable part of the record is the other five names teased in earlier presentations, which were down between roughly 15% and 65% as of the recent teardown. That spread is not unusual for a service that teases spinoffs, but it is the honest context for a “more than 8X bigger” opportunity claim, and it is why the specific name matters far more than the category it belongs to.

The Offer

Market Maven lists at $10,000 and is promoted at $2,500 for a year. There are no refunds. The “satisfaction guaranteed” language is a 30-day swap to another Stansberry Research service rather than a money-back guarantee, a detail that changes how you should read the order page. For the smaller of the two teased names, see our Versigent profile.

The Honest Read

The ISO framework has a real academic backbone, and Solstice Advanced Materials is a legitimate, sizable business that fits the carve-out pattern the promo describes. The case for caution is not the thesis but the price and the size. A near-$10 billion spinoff that has already ticked up since the tease is a different trade from the small, genuinely orphaned carve-outs where the historical edge is strongest. The framework is sound; the question is whether this specific name still carries the discount the pitch is selling.

If the spinoff framework itself is what you want to understand first, our spinoff stocks guide lays out how to evaluate any of these names, and the evidence behind the category is in our corporate spinoffs explainer.

What to Verify Before You Buy

Before you buy any teased spinoff, there is a short list of facts worth confirming for yourself, and Solstice Advanced Materials is large enough that most of them are checkable in public filings. Start with the parent: what was carved out, why, and whether the separation was a clean handoff or a way to offload a slower-growing division. Then look at the balance sheet the new company inherited, because a carve-out can arrive carrying more debt than the headline story suggests.

Next, check the cash flow. A spinoff that is cheap because it is being orphaned looks very different from one that is cheap because its economics are deteriorating, and the difference shows up in operating cash flow and margins over the first few quarters as a standalone. Finally, watch the shareholder base. For a near-$10 billion name, the forced selling from index funds is smaller in proportion to the float than it is for a micro-cap, which means the orphan discount here is likely to be shallower and to close faster.

The point of the checklist is not to find a reason to say no. It is to test the specific claim the pitch makes, that this particular company is cheap for mechanical reasons rather than fundamental ones. For a business this size, that test is runnable with public documents, and it is the difference between buying the thesis and buying a story.

Ready to see the research? Click here to access Gabe Marshank’s report.

NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.